Clinical trial
A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
NCT01238796 is registered in ClinicalTrials.gov with Cumberland Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
- Lead sponsor
- Cumberland Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2010
- Completion date
- February 28, 2011
- Enrollment
- 45 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
end stage renal disease, kidney diseases